妊娠期磷酸二酯酶-5抑制剂:母体与围产期安全性及临床结局的系统综述与Meta分析
该系统综述与Meta分析检索截至2021年9月的随机对照试验,纳入10项研究共1090名参与者,仅涉及他达拉非和西地那非。妊娠期使用磷酸二酯酶-5抑制剂与头痛、潮红、鼻出血等轻度母体副作用相关,非胎儿生长受限指征使用时阴道分娩增加且因产时胎儿窘迫的手术产风险降低,但用于治疗胎儿生长受限可能增加新生儿持续性肺动脉高压风险。
要点
- 妊娠期使用磷酸二酯酶-5抑制剂与头痛、潮红、鼻出血等轻度母体副作用相关。
- 非胎儿生长受限指征使用时,阴道分娩风险比1.24,因产时胎儿窘迫的手术产风险比0.58。
- 用于治疗胎儿生长受限时,新生儿持续性肺动脉高压风险比2.52。
核心结论
- 该Meta分析提示妊娠期使用磷酸二酯酶-5抑制剂与轻度母体副作用及因产时胎儿窘迫的手术产风险降低相关,用于治疗胎儿生长受限可能增加新生儿持续性肺动脉高压风险。
研究设计与样本
- 系统综述与Meta分析,检索Embase、PubMed、CENTRAL、Prospero和Google Scholar截至2021年9月,纳入报告妊娠期使用任何磷酸二酯酶-5抑制剂的随机对照试验,共纳入10项研究1090名参与者,其中2项使用他达拉非、8项使用西地那非,10项中9项评估为低偏倚风险。
主要发现
- 磷酸二酯酶-5抑制剂使用与头痛风险比1.41(95%CI 0.97-2.05)、潮红风险比2.59(95%CI 0.69-9.90)、鼻出血风险比10.53(95%CI 1.36-81.3)相关。
- 非胎儿生长受限指征使用时,阴道分娩风险比1.24(95%CI 1.00-1.55),因产时胎儿窘迫的手术产风险比0.58(95%CI 0.38-0.88)。
- 围产期死亡风险比0.89(95%CI 0.56-1.43),无风险增加的证据。
- 用于治疗胎儿生长受限时,新生儿持续性肺动脉高压风险比2.52(95%CI 1.00-6.32)。
临床怎么用
- 原文结论指出妊娠期使用磷酸二酯酶-5抑制剂与轻度母体副作用及因产时胎儿窘迫的手术产风险降低相关,用于治疗胎儿生长受限可能增加新生儿持续性肺动脉高压风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy and safety profile of phosphodiesterase-5 inhibitors (PDE-5i) in pregnancy are unclear from the few relatively small diverse studies that have used them. OBJECTIVE: To assess the safety profile and clinical outcomes of PDE-5i use in pregnancy. SEARCH STRATEGY: We searched Embase, PubMed, CENTRAL, Prospero and Google Scholar to identify randomised controlled trials (RCTs) reporting the use of any PDE-5i in pregnancy up to September 2021. SELECTION CRITERIA: RCTs reporting obstetric or perinatal outcomes or maternal adverse outcomes in women taking PDE5i in pregnancy. DATA COLLECTION AND ANALYSIS: Risk ratios (RR), 95% confidence intervals (95% CI) and 95% prediction intervals were calculated and pooled for analysis. RESULTS: We identified 1324 citations, of which 10 studies including 1090 participants met the inclusion criteria. Only tadalafil and sildenafil were reported as used in pregnancy. Two studies using tadalafil and eight sildenafil. Nine of ten studies were assessed at having of low risk of bias. PDE-5i use was associated with an increased risk of headaches (RR 1.41, 95% CI 0.97-2.05), flushing (RR 2.59, 95% CI 0.69-9.90) and nasal bleeding (RR 10.53, 95% CI 1.36-81.3); an increase in vaginal birth when used for non-fetal growth restriction (FGR) indications (RR 1.24, 95% CI 1.00-1.55) and a reduction in risk of operative birth for intrapartum fetal compromise (RR 0.58, 95% CI 0.38-0.88). There was no evidence of any increase in risk of perinatal death (RR 0.89, 95% CI 0.56-1.43). However, use for the treatment of FGR increased the risk of persistent pulmonary hypertension of the newborn (PPHN) (RR 2.52, 95% CI 1.00-6.32). CONCLUSIONS: This meta-analysis suggests PDE-5i use in pregnancy is associated with mild maternal side effects and lower risk of operative birth for intrapartum fetal distress. Prolonged use for the treatment of FGR may increase the risk of PPHN. TWEETABLE ABSTRACT: PDE-5i use in pregnancy is associated with mild maternal side effects, lower operative birth for intrapartum fetal distress and a possible increase in persistent pulmonary hypertension of the newborn when used for the treatment of fetal growth restriction.
引用
- Turner JM, Russo F, Deprest J, et al. Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. BJOG. 2022. PMID: 35352868. doi:10.1111/1471-0528.17163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。